Lipistad

Lipistad may be available in the countries listed below.

Ingredient matches for Lipistad

Atorvastatin

Atorvastatin is reported as an ingredient of Lipistad in the following countries:

• Vietnam

International Drug Name Search

Cimetag

Cimetag may be available in the countries listed below.

Ingredient matches for Cimetag

Cimetidine

Cimetidine is reported as an ingredient of Cimetag in the following countries:

• Austria


• Bahrain


• Israel


• Oman

International Drug Name Search

Eprosartan-ratiopharm

Eprosartan-ratiopharm may be available in the countries listed below.

Ingredient matches for Eprosartan-ratiopharm

Eprosartan

Eprosartan mesilate (a derivative of Eprosartan) is reported as an ingredient of Eprosartan-ratiopharm in the following countries:

• Germany

International Drug Name Search

Dafalgan Bébé

Dafalgan Bébé may be available in the countries listed below.

Ingredient matches for Dafalgan Bébé

Paracetamol

Paracetamol is reported as an ingredient of Dafalgan Bébé in the following countries:

• Belgium

International Drug Name Search

Farpain

Farpain may be available in the countries listed below.

Ingredient matches for Farpain

Ketorolac

Ketorolac tromethamine (a derivative of Ketorolac) is reported as an ingredient of Farpain in the following countries:

• Indonesia

International Drug Name Search

Ranibeta

Ranibeta may be available in the countries listed below.

Ingredient matches for Ranibeta

Ranitidine

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Ranibeta in the following countries:

• Germany

International Drug Name Search

Dygase

Pronunciation: a-mah-LASE/LYE-pase/PRO-tee-ase
Generic Name: Amylase/Lipase/Protease
Brand Name: Examples include Dygase and Lapase

Dygase is used for:

Relieving symptoms of indigestion (eg, feeling of fullness, gas, bloating) that occur after meals.

Dygase is a digestive enzyme combination. It works by helping the body to digest protein, starch, and fat.

Do NOT use Dygase if:

• you are allergic to any ingredient in Dygase or to pork protein


• you have inflammation of the pancreas (pancreatitis) or a flare-up of long-term pancreas problems

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dygase:

Some medical conditions may interact with Dygase. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of pancreas problems, stomach or bowel problems (eg, blockage, short bowel syndrome), or cystic fibrosis

Some MEDICINES MAY INTERACT with Dygase. However, no specific interactions with Dygase are known at this time.

Ask your health care provider if Dygase may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dygase:

Use Dygase as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Dygase by mouth with each meal or snack as directed by your doctor.


• Swallow Dygase whole. Do not break, crush, or chew before swallowing. If you cannot swallow the capsule whole, you may open it and sprinkle the contents over food. Mix the medicine with the food and swallow the entire mixture right away, followed by a glass of water.


• If you open the capsule, do not breathe in the powder. Some patients may experience an asthma attack or severe allergic reaction (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue) from breathing in the powder.


• If you miss a dose of Dygase, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once or take a dose without a snack or a meal.

Ask your health care provider any questions you may have about how to use Dygase.

Important safety information:

• This product may contain tartrazine dye (FD&C Yellow No. 5). This may cause an allergic reaction in some patients. If you have ever had an allergic reaction to tartrazine, ask your pharmacist if your product has tartrazine in it.


• Contact your doctor if you have loose stools while you take Dygase. Your doctor may need to decrease your dose


• PREGNANCY and BREAST-FEEDING: It is not known if Dygase can cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dygase while you are pregnant. It is not known if Dygase is found in breast milk. If you are or will be breast-feeding while you use Dygase, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Dygase:

All medicines may cause side effects, but many people have no, or minor, side effects. No COMMON side effects have been reported with Dygase. Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); severe or persistent loose stools; severe stomach pain.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Dygase side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center ( http://www.aapcc.org), or emergency room immediately. Symptoms may include diarrhea.

Proper storage of Dygase:

Store Dygase at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dygase out of the reach of children and away from pets.

General information:

• If you have any questions about Dygase, please talk with your doctor, pharmacist, or other health care provider.


• Dygase is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dygase. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Dygase resources

• Dygase Side Effects (in more detail)
• Dygase Use in Pregnancy & Breastfeeding
• Dygase Drug Interactions
• Dygase Support Group
• 0 Reviews for Dygase - Add your own review/rating

• Pancrelipase Prescribing Information (FDA)


• Pancrelipase Professional Patient Advice (Wolters Kluwer)


• Pancrelipase Monograph (AHFS DI)


• Creon Advanced Consumer (Micromedex) - Includes Dosage Information


• Creon Prescribing Information (FDA)


• Creon Consumer Overview


• Pancreaze Consumer Overview


• Pancreaze Prescribing Information (FDA)


• Zenpep Prescribing Information (FDA)


• Zenpep Consumer Overview

Compare Dygase with other medications

• Chronic Pancreatitis
• Cystic Fibrosis
• Pancreatic Exocrine Dysfunction

Etretinate

In the US, Etretinate is a member of the drug class antipsoriatics.

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

D05BB01

CAS registry number (Chemical Abstracts Service)

0054350-48-0

Chemical Formula

C23-H30-O3

Molecular Weight

354

Therapeutic Category

Dermatological agent: Antipsoriatic

Chemical Name

2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)-

Foreign Names

• Etretinatum (Latin)
• Etretinat (German)
• Etrétinate (French)
• Etretinato (Spanish)

Generic Names

• Etretinate (OS: USAN, JAN, BAN)
• Étrétinate (OS: DCF)
• Etretinato (OS: DCIT)
• Ro 10-9359 (IS)
• Ro 10-9359-9 (IS)

Brand Name

• Tigason
  Chugai, Japan

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Sulamid

Sulamid may be available in the countries listed below.

Ingredient matches for Sulamid

Amisulpride

Amisulpride is reported as an ingredient of Sulamid in the following countries:

• Italy

International Drug Name Search

bacitracin, neomycin, and polymyxin B ophthalmic

Generic Name: bacitracin, neomycin, and polymyxin B ophthalmic (BAS i TRAY sin, NEE oh MYE sin, POL ee MIX in off THAL mik)

Brand names: Ocu-Spore-B, Ocutricin, AK-Spore Ointment, Neocin, Neosporin ophthalmic ointment, Neo-Polycin

What is bacitracin, neomycin, and polymyxin B ophthalmic?

Bacitracin, neomycin, and polymyxin B are antibiotics that kill bacteria.

Bacitracin, neomycin, and polymyxin B ophthalmic (for the eyes) is used to treat eye infections caused by bacteria.

Bacitracin, neomycin, and polymyxin B ophthalmic may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about bacitracin, neomycin, and polymyxin B ophthalmic?

You should not use this medication if you are allergic to bacitracin, neomycin, or polymyxin B. Do not allow the tip of the ointment tube to touch any surface, including the eyes or hands. If the tip becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye. Do not share the ointment with another person.

Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Bacitracin, neomycin, and polymyxin B ophthalmic will not treat a viral or fungal infection of the eye.

Call your doctor if your symptoms do not improve, or if your infection gets worse while using this medication.

If you use this medication long-term, you may need frequent eye exams to make sure this medication is not causing harmful effects. Do not miss any follow-up visits to your doctor.

Bacitracin, neomycin, and polymyxin B should not be used on a child.

What should I discuss with my healthcare provider before using bacitracin, neomycin, and polymyxin B ophthalmic?

You should not use this medication if you are allergic to bacitracin, neomycin, or polymyxin B. FDA pregnancy category C. It is not known whether bacitracin, neomycin, and polymyxin B ophthalmic is harmful to an unborn baby. Before taking this medication, tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether bacitracin, neomycin, and polymyxin B ophthalmic passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Bacitracin, neomycin, and polymyxin B should not be used on a child.

How should I use bacitracin, neomycin, and polymyxin B ophthalmic?

Use this medication exactly as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended. Follow the directions on your prescription label.

Wash your hands before using bacitracin, neomycin, and polymyxin B ophthalmic ointment.

To use the ointment:

• 
  

  You may warm the ointment by holding the medicine tube in your hand for a few minutes before use. Do not remove the cap from the tube until you are ready to apply the ointment.

  
  


• 
  

  Tilt your head back slightly, and pull down gently on your lower eyelid. Apply a thin film of the ointment into your lower eyelid.

  
  


• 
  

  Close your eye and roll your eyeball around for 1 to 2 minutes.

  
  

Do not allow the tip of the ointment tube to touch any surface, including the eyes or hands. If the tip becomes contaminated it could cause an infection in your eye, which can lead to vision loss or serious damage to the eye. Do not share the ointment with another person.

Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Bacitracin, neomycin, and polymyxin B ophthalmic will not treat a viral or fungal infection of the eye.

Call your doctor if your symptoms do not improve, or if your infection gets worse while using this medication.

If you use this medication long-term, you may need frequent eye exams to make sure this medication is not causing harmful effects. Do not miss any follow-up visits to your doctor.

Store bacitracin, neomycin, and polymyxin B ophthalmic at room temperature away from moisture and heat. Keep the tube tightly capped when not in use.

What happens if I miss a dose?

Use the medication as soon as you remember the missed dose. If it is almost time for your next dose, skip the missed dose and use the medicine at your next regularly scheduled time. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

An overdose of bacitracin, neomycin, and polymyxin B ophthalmic is not likely to occur.

What should I avoid while using bacitracin, neomycin, and polymyxin B ophthalmic?

Do not use any other eye medications unless your doctor has prescribed them.

Bacitracin, neomycin, and polymyxin B ophthalmic can cause temporary blurred vision. Be careful if you drive or do anything that requires you to be able to see clearly.

Bacitracin, neomycin, and polymyxin B ophthalmic side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have a serious side effect such as:

• 
  

  severe itching, watering, redness, or swelling of your eyes;

  
  


• 
  

  eye pain;

  
  


• 
  

  crusting or drainage from your eyes; or

  
  


• 
  

  any new signs of infection.

  
  

Less serious side effects may include temporary blurred vision and mild eye irritation after using the ointment.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Bacitracin, neomycin, and polymyxin B ophthalmic Dosing Information

Usual Adult Dose for Bacterial Conjunctivitis:

Apply to the affected eye(s) every 3 to 4 hours for 7 to 10 days

Usual Adult Dose for Keratitis:

Apply to the affected eye(s) every 3 to 4 hours for 7 to 10 days

Usual Adult Dose for Keratoconjunctivitis:

Apply to the affected eye(s) every 3 to 4 hours for 7 to 10 days

Usual Adult Dose for Blepharitis:

Apply to the affected eye(s) every 3 to 4 hours for 7 to 10 days

Usual Adult Dose for Blepharoconjunctivitis:

Apply to the affected eye(s) every 3 to 4 hours for 7 to 10 days

What other drugs will affect bacitracin, neomycin, and polymyxin B ophthalmic?

It is not likely that other drugs you take orally or inject will have an effect on bacitracin, neomycin, and polymyxin B ophthalmic used in the eyes. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

More bacitracin, neomycin, and polymyxin B ophthalmic resources

• Bacitracin, neomycin, and polymyxin B ophthalmic Dosage
• Bacitracin, neomycin, and polymyxin B ophthalmic Use in Pregnancy & Breastfeeding
• Bacitracin, neomycin, and polymyxin B ophthalmic Support Group
• 1 Review for Bacitracin, neomycin, and polymyxin B - Add your own review/rating

Compare bacitracin, neomycin, and polymyxin B ophthalmic with other medications

• Blepharitis
• Blepharoconjunctivitis
• Conjunctivitis, Bacterial
• Keratitis
• Keratoconjunctivitis

Where can I get more information?

• Your pharmacist can provide more information about bacitracin, neomycin, and polymyxin B ophthalmic.

Relion Novolin 70/30 Innolet

Generic Name: insulin isophane and insulin regular (IN su lin EYE soe fane and IN su lin REG ue lar)

Brand Names: HumuLIN 50/50, HumuLIN 70/30, HumuLIN 70/30 Pen, NovoLIN 70/30, NovoLIN 70/30 Innolet, NovoLIN 70/30 PenFill, Relion NovoLIN 70/30 Innolet, ReliOn/NovoLIN 70/30

What is Relion Novolin 70/30 Innolet (insulin isophane and insulin regular)?

Insulin isophane and insulin regular is a man-made form of a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. Insulin isophane and insulin regular is a long-acting form of insulin that is slightly different from other forms of insulin that are not man-made.

Insulin isophane and insulin regular is used to treat diabetes.

Insulin isophane and insulin regular may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about Relion Novolin 70/30 Innolet (insulin isophane and insulin regular)?

Take care to keep your blood sugar from getting too low, causing hypoglycemia. Symptoms of low blood sugar may include headache, nausea, hunger, confusion, drowsiness, weakness, dizziness, blurred vision, fast heartbeat, sweating, tremor, or trouble concentrating. Carry a piece of non-dietetic hard candy or glucose tablets with you in case you have low blood sugar. Also be sure your family and close friends know how to help you in an emergency.

Also watch for signs of blood sugar that is too high (hyperglycemia). These symptoms include increased thirst, loss of appetite, increased urination, nausea, vomiting, drowsiness, dry skin, and dry mouth. Check your blood sugar levels and ask your doctor how to adjust your insulin doses if needed.

Never share an injection pen or cartridge with another person. Sharing injection pens or cartridges can allow disease such as hepatitis or HIV to pass from one person to another.

Insulin isophane and insulin regular is only part of a complete program of treatment that may also include diet, exercise, weight control, foot care, eye care, dental care, and testing your blood sugar. Follow your diet, medication, and exercise routines very closely. Changing any of these factors can affect your blood sugar levels.

What should I discuss with my healthcare provider before using Relion Novolin 70/30 Innolet (insulin isophane and insulin regular)?

Do not use this medication if you are allergic to insulin, or if you are having an episode of hypoglycemia (low blood sugar).

Before using insulin isophane and insulin regular, tell your doctor if you have liver or kidney disease.

Tell your doctor about all other medications you use, including any oral (by mouth) diabetes medications.

Insulin isophane and insulin regular is only part of a complete program of treatment that may also include diet, exercise, weight control, foot care, eye care, dental care, and testing your blood sugar. Follow your diet, medication, and exercise routines very closely. Changing any of these factors can affect your blood sugar levels.

Your doctor will need to check your progress on a regular basis. Do not miss any scheduled appointments.

FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether insulin isophane and insulin regular passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use Relion Novolin 70/30 Innolet (insulin isophane and insulin regular)?

Use this medication exactly as it was prescribed for you. Do not use it in larger amounts or for longer than recommended by your doctor. Follow the directions on your prescription label.

Insulin isophane and insulin regular is given as an injection (shot) under your skin. Your doctor, nurse, or pharmacist will give you specific instructions on how and where to inject this medicine. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles and syringes.

Choose a different place in your injection skin area each time you use this medication. Do not inject into the same place two times in a row.

Carefully shake or rotate the insulin vial (bottle) several times to thoroughly mix the insulin isophane and insulin regular before each use. Shake the mixture until it looks cloudy or milky. Do not use the mixture if has clumps or white particles in it after mixing, or if the white substance remains at the bottom of the vial. Call your doctor for a new prescription.

Use each disposable needle only one time. Throw away used needles in a puncture-proof container (ask your pharmacist where you can get one and how to dispose of it). Keep this container out of the reach of children and pets.

Some insulin needles can be used more than once, depending on needle brand and type. But a reused needle must be properly cleaned, recapped, and inspected for bending or breakage. Reusing needles also increases your risk of infection. Ask your doctor or pharmacist whether you are able to reuse your insulin needles.

Never share an injection pen or cartridge with another person. Sharing injection pens or cartridges can allow disease such as hepatitis or HIV to pass from one person to another.

Check your blood sugar carefully during a time of stress or illness, if you travel, exercise more than usual, or skip meals. These things can affect your glucose levels and your insulin dose needs may also change.

Watch for signs of blood sugar that is too high (hyperglycemia). These symptoms include increased thirst, loss of appetite, increased urination, nausea, vomiting, drowsiness, dry skin, and dry mouth. Check your blood sugar levels and ask your doctor how to adjust your insulin doses if needed.

Ask your doctor how to adjust your insulin isophane and insulin regular dose if needed. Do not change your dose without first talking to your doctor. Carry an ID card or wear a medical alert bracelet stating that you have diabetes, in case of emergency. Any doctor, dentist, or emergency medical care provider who treats you should know that you are diabetic. Storing unopened vials or injection pens: Keep in the carton and store in a refrigerator. Do not freeze. Throw away any insulin not used before the expiration date on the medicine label. Storing after your first use: Keep the "in-use" vials or injection pens at cool room temperature, away from heat and light, and use prior to the expiration date. Throw an in-use injection pen 10 days after the first use, even if there is still medicine left in it.

Do not freeze insulin isophane and insulin regular, and throw away the medication if it has become frozen.

What happens if I miss a dose?

Since insulin isophane and insulin regular is used before meals or snacks, you may not be on a timed dosing schedule. Whenever you use insulin isophane and insulin regular, be sure to eat a meal or snack within 30 to 60 minutes. Do not use extra insulin isophane and insulin regular to make up a missed dose.

It is important to keep insulin isophane and insulin regular on hand at all times. Get your prescription refilled before you run out of medicine completely.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine. An insulin overdose can cause life-threatening hypoglycemia.

Symptoms of severe hypoglycemia include extreme weakness, blurred vision, sweating, trouble speaking, tremors, stomach pain, confusion, seizure (convulsions), or coma.

What should I avoid while using Relion Novolin 70/30 Innolet (insulin isophane and insulin regular)?

Do not change the brand of insulin isophane and insulin regular or syringe you are using without first talking to your doctor or pharmacist. Avoid drinking alcohol. Your blood sugar may become dangerously low if you drink alcohol while using insulin isophane and insulin regular.

Relion Novolin 70/30 Innolet (insulin isophane and insulin regular) side effects

Get emergency medical help if you have any of these signs of insulin allergy: itching skin rash over the entire body, wheezing, trouble breathing, fast heart rate, sweating, or feeling like you might pass out.

Hypoglycemia, or low blood sugar, is the most common side effect of insulin isophane and insulin regular. Symptoms of low blood sugar may include headache, nausea, hunger, confusion, drowsiness, weakness, dizziness, blurred vision, fast heartbeat, sweating, tremor, trouble concentrating, confusion, or seizure (convulsions). Watch for signs of low blood sugar. Carry a piece of non-dietetic hard candy or glucose tablets with you in case you have low blood sugar.

Tell your doctor if you have itching, swelling, redness, or thickening of the skin where you inject insulin isophane and insulin regular.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Relion Novolin 70/30 Innolet (insulin isophane and insulin regular)?

Using certain medicines can make it harder for you to tell when you have low blood sugar. Tell your doctor if you use any of the following:

• 
  

  albuterol (Proventil, Ventolin);

  
  


• 
  

  clonidine (Catapres);

  
  


• 
  

  reserpine;

  
  


• 
  

  guanethidine (Ismelin); or

  
  


• 
  

  beta-blockers such as atenolol (Tenormin), bisoprolol (Zebeta), labetalol (Normodyne, Trandate), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), timolol (Blocadren), and others.

  
  

There are many other medicines that can increase or decrease the effects of insulin isophane and insulin regular on lowering your blood sugar. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor. Keep a list with you of all the medicines you use and show this list to any doctor or other healthcare provider who treats you.

More Relion Novolin 70/30 Innolet resources

• Relion Novolin 70/30 Innolet Side Effects (in more detail)
• Relion Novolin 70/30 Innolet Use in Pregnancy & Breastfeeding
• Relion Novolin 70/30 Innolet Drug Interactions
• 1 Review for Relion Novolin 70/30 Innolet - Add your own review/rating

• Humulin 50/50 Pens MedFacts Consumer Leaflet (Wolters Kluwer)


• Humulin 50/50 Prescribing Information (FDA)


• Humulin 70/30 Prescribing Information (FDA)


• Novolin 70/30 Prescribing Information (FDA)


• Novolin 70/30 InnoLets MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Relion Novolin 70/30 Innolet with other medications

• Diabetes, Type 1
• Diabetes, Type 2
• Gestational Diabetes

Where can I get more information?

• Your pharmacist can provide more information about insulin isophane and insulin regular.

See also: Relion Novolin 70/30 Innolet side effects (in more detail)

Sirdalud MR

Sirdalud MR may be available in the countries listed below.

Ingredient matches for Sirdalud MR

Tizanidine

Tizanidine hydrochloride (a derivative of Tizanidine) is reported as an ingredient of Sirdalud MR in the following countries:

• Switzerland

International Drug Name Search

Glibenclamide Mylan

Glibenclamide Mylan may be available in the countries listed below.

Ingredient matches for Glibenclamide Mylan

Glibenclamide

Glibenclamide is reported as an ingredient of Glibenclamide Mylan in the following countries:

• France

International Drug Name Search

Nezeril

Nezeril may be available in the countries listed below.

Ingredient matches for Nezeril

Oxymetazoline

Oxymetazoline hydrochloride (a derivative of Oxymetazoline) is reported as an ingredient of Nezeril in the following countries:

• Iceland


• Sweden

International Drug Name Search

Butabarbital Sodium

Ingredient matches for Butabarbital Sodium

Secbutabarbital

Secbutabarbital sodium (a derivative of Secbutabarbital) is reported as an ingredient of Butabarbital Sodium in the following countries:

• United States

International Drug Name Search

Ultrasef

Ultrasef may be available in the countries listed below.

Ingredient matches for Ultrasef

Cefradine

Cefradine is reported as an ingredient of Ultrasef in the following countries:

• Bangladesh

International Drug Name Search

Captopril-HCT Ratiopharm

Captopril-HCT Ratiopharm may be available in the countries listed below.

Ingredient matches for Captopril-HCT Ratiopharm

Captopril

Captopril is reported as an ingredient of Captopril-HCT Ratiopharm in the following countries:

• Austria

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Captopril-HCT Ratiopharm in the following countries:

• Austria

International Drug Name Search

Zip-A-Dol

Zip-A-Dol may be available in the countries listed below.

Ingredient matches for Zip-A-Dol

Ibuprofen

Ibuprofen is reported as an ingredient of Zip-A-Dol in the following countries:

• Portugal

International Drug Name Search

Alizin

Alizin may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Alizin

Aglepristone

Aglepristone is reported as an ingredient of Alizin in the following countries:

• Australia


• Belgium


• Finland


• Germany


• Italy


• Luxembourg


• Netherlands


• New Zealand


• Norway


• Poland


• Portugal


• Sweden


• Switzerland


• United Kingdom

International Drug Name Search

Reno-30

Dosage Form: injection

NOT FOR INTRATHECAL USE

For retrograde pyelography

Not intended for intravascular injection

Reno-30 Description

Reno-30 is a radiopaque contrast agent for retrograde pyelography supplied as a sterile, aqueous solution. Each mL provides 300 mg diatrizoate meglumine with 3.2 mg sodium citrate as a buffer, 0.4 mg edetate disodium as a sequestering agent, and 1 mg methylparaben and 0.3 mg propylparaben as preservatives. Each mL of solution also contains approximately 141 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen.

INDICATIONS

Reno-30 is intended for retrograde or ascending pyelography. This procedure may be used if intravenous excretion urography is contraindicated and it is also useful in complementing other diagnostic information.

Contraindications

Reno-30 is contraindicated for use in intrathecal procedures.

Contraindications pertain to the procedure of retrograde pyelography rather than to the administration of the medium per se. Retrograde pyelography should not be performed in those conditions which do not allow for the successful catheterization of the ureters such as extensive urinary tuberculosis, tumors of the bladder, impassable obstructions of the ureters, or marked enlargement of the prostate gland.

Warnings

Severe Adverse Events—Inadvertent Intrathecal Administration

Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to insure that this drug product is not inadvertently administered intrathecally.

The possibility exists for inadvertent administration into the intrathecal space during epidural administrations. Therefore, epidural administration procedures, such as pain management catheter placement, should not be performed with use of this product.

General

Apart from the possible adverse effects of diatrizoate meglumine, the hazards of the performance of a retrograde genitourinary procedure exist. These include such complications as hematuria, perforation of the ureter or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria.

Precautions

Because of the possibility of inducing temporary suppression of urine, it is wise to avoid repetition of retrograde pyelography within 48 hours in patients with reduced renal function.

Retrograde pyelography should be performed with caution in patients with a known active infectious process of the urinary tract.

Contrast agents may interfere with some chemical determinations made on urine specimens; therefore, urine should be collected before administration of the contrast medium or two or more days afterwards.

Adverse Reactions

The incidence of adverse reactions with diatrizoate meglumine is very low. Costovertebral angle tenderness, elevated temperature and flank pain have been reported in a few patients following use of the preparation for retrograde pyelography, as have nausea, sweating and flushing.

Irritation of the urinary tract mucosa attributable to the contrast agent itself is not likely to occur. However, the technique of retrograde pyelography may be painful and may initiate pelvic, caliceal, or ureteral spasms with consequent renal colic.

Since retrograde pyelography does not involve systemic administration of a contrast agent, the risk of severe reactions, which may occur with intravenous administration, is extremely remote. However, they should be kept in mind whenever a contrast agent is administered. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions, or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs. Like other sensitivity phenomena, severe reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, drug reactions, or previous reactions to contrast agents.

Reno-30 Dosage and Administration

Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended.

Dosage: The usual dose for patients aged 16 years or more is 15 mL for unilateral and appropriately increased volumes for bilateral pyelograms. Approximately 5 to 6 mL will generally be required for each exposure. The dosage for children should be proportionately smaller than the adult dose.

As supplied, the preparation provides maximum opacification. If a lesser contrast is desired, it may be diluted with sterile distilled water.

Administration: Reno-30 may be introduced by a gravity flow system or by syringe. When the syringe method is used, the injections should be made slowly and care should be exercised to use as little manual pressure as possible. Regardless of the system used, injection of the contrast medium should be terminated as soon as the patient complains of a sense of fullness or pain in the renal region.

Radiography: The commonly employed radiographic techniques should be used. A scout film is recommended before the contrast agent is administered.

How is Reno-30 Supplied

Reno-30 (Diatrizoate Meglumine Injection USP 30%) is available in packages of: Twenty-five 50 mL multiple dose vials (NDC 0270-0804-45).

Storage

The preparation should be protected from strong light and stored at 20–25°C (68–77°F) [See USP]; avoid freezing.

Manufactured for

Bracco Diagnostics Inc.

Princeton, NJ 08543

by SICOR Pharmaceuticals, Inc.

Irvine, CA 92618

Revised September 2003

Printed in USA

Reno-30  diatrizoate meglumine  injection, solution

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 0270-0804 Route of Administration INTRAVENOUS DEA Schedule

INGREDIENTS Name (Active Moiety) Type Strength diatrizoate meglumine (diatrizoic acid) Active 300 MILLIGRAM  In 1 MILLILITER edetate disodium Inactive 0.4 MILLIGRAM  In 1 MILLILITER methylparaben Inactive 1 MILLIGRAM  In 1 MILLILITER propylparaben Inactive 0.3 MILLIGRAM  In 1 MILLILITER sodium citrate Inactive 3.2 MILLIGRAM  In 1 MILLILITER

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 0270-0804-45 25 VIAL In 1 PACKAGE contains a VIAL 1 50 mL (MILLILITER) In 1 VIAL This package is contained within the PACKAGE (0270-0804-45)

Revised: 03/2007Bracco Diagnostics Inc.

More Reno-30 resources

• Reno-30 Side Effects (in more detail)
• Reno-30 Dosage
• Reno-30 Drug Interactions
• Reno-30 Support Group
• 0 Reviews · Be the first to review/rate this drug

• Diatrizoate Meglumine Professional Patient Advice (Wolters Kluwer)

Intron-A Multid. Pen

Intron-A Multid. Pen may be available in the countries listed below.

Ingredient matches for Intron-A Multid. Pen

Interferon alfa

Interferon alfa Interferon alfa-2b (Arg-23; His-34) (a derivative of Interferon alfa) is reported as an ingredient of Intron-A Multid. Pen in the following countries:

• Peru

International Drug Name Search

Glicerolo Ramini

Glicerolo Ramini may be available in the countries listed below.

Ingredient matches for Glicerolo Ramini

Glycerol

Glycerol is reported as an ingredient of Glicerolo Ramini in the following countries:

• Italy

International Drug Name Search

Amyline

Amyline may be available in the countries listed below.

Ingredient matches for Amyline

Glimepiride

Glimepiride is reported as an ingredient of Amyline in the following countries:

• Ecuador

International Drug Name Search

Rosadan Cream

Generic Name: metronidazole

Dosage Form: cream
Rosadan™

Metronidazole Topical Cream, 0.75%

FOR TOPICAL USE ONLY (NOT FOR OPHTHALMIC USE)

Rx only

Rosadan Cream Description

Rosadan™ (metronidazole) Topical Cream contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75%) in an emollient cream consisting of emulsifying wax, sorbitol solution, glycerin, isopropyl palmitate, benzyl alcohol, lactic acid and/or sodium hydroxide to adjust pH, and purified water. Metronidazole is a member of the imidazole class of anti-bacterial agents and is classified therapeutically as an antiprotozoal and antibacterial agent. Chemically, metronidazole is 2-methyl-5-nitro-1H-imidazole-1-ethanol. The molecular formula is C6H9N3O3 and molecular weight is 171.16. Metronidazole is represented by the following structural formula:

Rosadan Cream - Clinical Pharmacology

The mechanisms by which metronidazole acts in the treatment of rosacea are unknown, but appear to include an anti-inflammatory effect.

Indications and Usage for Rosadan Cream

Rosadan™ (metronidazole) Topical Cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.

Contraindications

Rosadan™ (metronidazole) Topical Cream is contraindicated in individuals with a history of hypersensitivity to metronidazole, or other ingredients of the formulation.

Precautions

General

Topical metronidazole has been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence of, or history of blood dyscrasia.

Information for patients

This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.

Drug Interactions

Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of prothrombin time. The effect of topical metronidazole on prothrombin time is not known.

Carcinogenesis, mutagenesis, impairment of fertility

Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters.

Metronidazole has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-response increase in the frequency of micronuclei was observed in mice after intraperitoneal injections and an increase in chromosome aberrations have been reported in patients with Crohn's disease who were treated with 200-1200 mg/day of metronidazole for 1 to 24 months. However, no excess chromosomal aberrations in circulating human lymphocytes have been observed in patients treated for 8 months.

Pregnancy

Teratogenic effects

Pregnancy category B

There are no adequate and well-controlled studies with the use of Rosadan™ (metronidazole) Topical Cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.

Nursing mothers

After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric use

Safety and effectiveness in pediatric patients have not been established.

Adverse Reactions

In controlled clinical trials, the total incidence of adverse reactions associated with the use of topical metronidazole cream was approximately 10%. Skin discomfort (burning and stinging) was the most frequently reported event followed by erythema, skin irritation, pruritus and worsening of rosacea. All individual events occurred in less than 3% of patients.

The following additional adverse experiences have been reported with the topical use of metronidazole: dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea.

Rosadan Cream Dosage and Administration

Apply and rub in a thin layer of Rosadan™ (metronidazole) Topical Cream twice daily, morning and evening, to entire affected areas after washing.

Areas to be treated should be washed with a mild cleanser before application. Patients may use cosmetics after application of Rosadan™ (metronidazole) Topical Cream.

How is Rosadan Cream Supplied

Rosadan™ (metronidazole) Topical Cream, 0.75% is supplied in a 45 g tube - NDC 43538-180-45.

Storage conditions

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured for:

MEDIMETRIKS

PHARMACEUTICALS, INC.

363 Route 46 West

Fairfield, NJ 07004-2402 USA

www.medimetriks.com

Manufactured by:

G&W Laboratories, Inc.

South Plainfield, NJ 07080

IP019

8-0633MDM1

Issued 02/11

PRINCIPAL DISPLAY PANEL - 45 g Tube Carton

MEDIMETRIKS

PHARMACEUTICALS, INC.

NDC 43538-180-45

RX Only

Rosadan™

Metronidazole Topical Cream, 0.75%

NET WT 45 g

PRINCIPAL DISPLAY PANEL - Kit Carton

NDC 43538-181-45

RX Only

Rosadan™

Metronidazole Topical Cream, 0.75%

CREAM KIT

CONTENTS:

1-Rosadan™ Metronidazole Topical Cream, 0.75% Tube (Net wt. 45 g)

1-Rehyla™ Wash Moisturizing Daily Wash Bottle (16 fl. oz.)

MEDIMETRIKS

PHARMACEUTICALS, INC.

ROSADAN  metronidazole  cream

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 43538-180 Route of Administration TOPICAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength metronidazole (metronidazole) metronidazole 7.5 mg  in 1 g

Inactive Ingredients Ingredient Name Strength sorbitol   glycerin   isopropyl palmitate   benzyl alcohol   lactic acid   sodium hydroxide   water

Product Characteristics Color WHITE Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 43538-180-45 45 g In 1 TUBE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA077549	08/30/2011

ROSADAN  metronidazole  cream

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 43538-181 Route of Administration TOPICAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength metronidazole (metronidazole) metronidazole 7.5 mg  in 1 g

Inactive Ingredients Ingredient Name Strength sorbitol   glycerin   isopropyl palmitate   benzyl alcohol   lactic acid   sodium hydroxide   water

Product Characteristics Color WHITE Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 43538-181-45 1 TUBE In 1 KIT contains a TUBE 1 45 g In 1 TUBE This package is contained within the KIT (43538-181-45)

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA077549	08/30/2011

Labeler - Medimetriks Pharmaceuticals, Inc. (019903816)

Establishment
Name	Address	ID/FEI	Operations
G&W Laboratories		001271188	MANUFACTURE

Revised: 08/2011Medimetriks Pharmaceuticals, Inc.

More Rosadan Cream resources

• Rosadan Cream Use in Pregnancy & Breastfeeding
• Rosadan Cream Drug Interactions
• Rosadan Cream Support Group
• 15 Reviews for Rosadan - Add your own review/rating

Compare Rosadan Cream with other medications

• Bacterial Vaginitis
• Perioral Dermatitis
• Rosacea

Epilat

Epilat may be available in the countries listed below.

Ingredient matches for Epilat

Nifedipine

Nifedipine is reported as an ingredient of Epilat in the following countries:

• Bahrain


• Ethiopia


• Iraq


• Jordan


• Kuwait


• Lebanon


• Libya


• Oman


• Qatar


• Romania


• Saudi Arabia


• Sudan


• United Arab Emirates


• Yemen

International Drug Name Search

Lizpion

Lizpion may be available in the countries listed below.

Ingredient matches for Lizpion

Lincomycin

Lincomycin hydrochloride monohydrate (a derivative of Lincomycin) is reported as an ingredient of Lizpion in the following countries:

• Japan

International Drug Name Search

Nifedicor

Nifedicor may be available in the countries listed below.

Ingredient matches for Nifedicor

Nifedipine

Nifedipine is reported as an ingredient of Nifedicor in the following countries:

• Greece


• Italy

International Drug Name Search

Losargamma

Losargamma may be available in the countries listed below.

Ingredient matches for Losargamma

Losartan

Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losargamma in the following countries:

• Germany

International Drug Name Search

Pentoxyverine

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

R05DB05

CAS registry number (Chemical Abstracts Service)

0000077-23-6

Chemical Formula

C20-H31-N-O3

Molecular Weight

333

Therapeutic Category

Cough suppressant

Chemical Name

Cyclopentanecarboxylic acid, 1-phenyl-, 2-[2-(diethylamino)ethoxy]ethyl ester

Foreign Names

• Pentoxyverinum (Latin)
• Pentoxyverin (German)
• Pentoxyvérine (French)
• Pentoxiverina (Spanish)

Generic Names

• Pentoxiverina (OS: DCIT)
• Pentoxyverine (OS: BAN)
• Pentoxyvérine (OS: DCF)
• Carbapentane (IS)
• Tusolven (IS)
• UCB 2543 (IS)
• Pentoxyverine citrate (OS: JAN, BANM)
• Carbetapentane Citrate (IS)
• Pentoxyvérine (hydrogénocitrate) (PH: Ph. Eur. 6)
• Pentoxyverine Citrate (PH: JP XIV, BP 2010)
• Pentoxyverine Hydrogen Citrate (PH: Ph. Eur. 6)
• Pentoxyverinhydrogencitrat (PH: Ph. Eur. 6)
• Pentoxyverini hydrogencitras (PH: Ph. Eur. 6)

Brand Names

• Balsoclase E
  Pierre Fabre, Netherlands



• Sedotussin
  UCB, Austria; UCB, Germany



• Astomatop
  Tsuruhara Seiyaku, Japan



• Balsoclase Comp.
  UCB, Netherlands



• Balsoclase
  Pierre Fabre, Belgium; Pierre Fabre, Netherlands; UCB, Luxembourg



• Balsoclase Antitussivum Enfant
  Pierre Fabre, Belgium



• Balsoclase Antitussivum Jeune Enfant (pediatric)
  Pierre Fabre, Belgium



• Calnathal TP
  Zensei Yakuhin, Japan



• Fuszemin CP
  Taiyo Pharmaceutical, Japan



• Gai less
  Isei, Japan



• Patcon
  Nippon Universal Pharmaceutical, Japan



• Pectosan
  Cooper, France



• Pentoxyverine C-Dragon Pharmacy
  C-Dragon, China



• Sedotussin
  UCB, Austria; UCB, Germany; UCB, Hungary



• Statomin
  Choseido Pharmaceutical, Japan



• Takabetan
  Takata Seiyaku, Japan



• Toclase
  Dainippon Sumitomo, Japan; UCB, Estonia; UCB, Finland; UCB, France; UCB, Lithuania; UCB, Philippines; UCB, Thailand; UCB, Taiwan



• Vicks
  Procter & Gamble, France



• Sedotussin
  UCB, Hungary



• Toclase
  UCB, Finland; UCB, Latvia; UCB, Oman; UCB, Thailand; UCB, Turkey; UCB Pharma, Malta



• Tuclase
  Pierre Fabre, Netherlands; UCB, Greece; UCB, Italy; UCB, Luxembourg

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Altis

Altis may be available in the countries listed below.

Ingredient matches for Altis

Ketoconazole

Ketoconazole is reported as an ingredient of Altis in the following countries:

• Estonia


• Latvia


• Lithuania

International Drug Name Search

Trimosulf

Trimosulf may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Trimosulf

Sulfadiazine

Sulfadiazine is reported as an ingredient of Trimosulf in the following countries:

• Germany

Sulfadoxine

Sulfadoxine is reported as an ingredient of Trimosulf in the following countries:

• Germany

Trimethoprim

Trimethoprim is reported as an ingredient of Trimosulf in the following countries:

• Germany

Trimethoprim lactate (a derivative of Trimethoprim) is reported as an ingredient of Trimosulf in the following countries:

• Germany

International Drug Name Search

Bio Crem A

Bio Crem A may be available in the countries listed below.

Ingredient matches for Bio Crem A

Retinol

Retinol palmitate (a derivative of Retinol) is reported as an ingredient of Bio Crem A in the following countries:

• Peru

International Drug Name Search

Acetato De Ciproterona Etinilestradiol Davur

Acetato De Ciproterona Etinilestradiol Davur may be available in the countries listed below.

Ingredient matches for Acetato De Ciproterona Etinilestradiol Davur

Cyproterone

Cyproterone 17α-acetate (a derivative of Cyproterone) is reported as an ingredient of Acetato De Ciproterona Etinilestradiol Davur in the following countries:

• Spain

Ethinylestradiol

Ethinylestradiol is reported as an ingredient of Acetato De Ciproterona Etinilestradiol Davur in the following countries:

• Spain

International Drug Name Search

Gentamicin Injection BP

Gentamicin Injection BP may be available in the countries listed below.

Ingredient matches for Gentamicin Injection BP

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Gentamicin Injection BP in the following countries:

• Australia


• New Zealand

International Drug Name Search

Duo-Vil 2-10

Generic Name: perphenazine and amitriptyline (Oral route)

per-FEN-a-zeen, am-i-TRIP-ti-leen hye-droe-KLOR-ide

Oral route(Tablet)

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Although the causes of death in clinical trials were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that antipsychotic drugs may increase mortality. It is unclear from these studies to what extent the mortality findings may be attributed to the antipsychotic drug as opposed to patient characteristics. Perphenazine and amitriptyline hydrochloride is not approved for the treatment of patients with dementia-related psychosis. Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Perphenazine and amitriptyline hydrochloride is not approved for use in pediatric patients .

Commonly used brand name(s)

In the U.S.

• Duo-Vil 2-10


• Duo-Vil 2-25


• Etrafon

Available Dosage Forms:

• Tablet

Therapeutic Class: Tricyclic Antidepressant/Phenothiazine Combination

Pharmacologic Class: Phenothiazine

Chemical Class: Piperazine (class)

Uses For Duo-Vil 2-10

Perphenazine and amitriptyline combination is used to treat certain mental and emotional conditions.

This combination is available only with your doctor's prescription.

Before Using Duo-Vil 2-10

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Certain side effects, such as muscle spasms of the face, neck, and back, tic-like or twitching movements, inability to move the eyes, twisting of the body, or weakness of the arms and legs, are more likely to occur in children, who are usually more sensitive than adults to some of the side effects of perphenazine and amitriptyline combination.

The perphenazine and amitriptyline combination must be used with caution in children with depression. Studies have shown occurrences of children thinking about suicide or attempting suicide in clinical trials for this medicine. More study is needed to be sure the perphenazine and amitriptyline combination is safe and effective in children

Geriatric

Confusion, vision problems, dizziness or fainting, drowsiness, dryness of mouth, constipation, problems in urinating, trembling of the hands and fingers, and symptoms of tardive dyskinesia (such as uncontrolled movements of the mouth, tongue, jaw, arms, and/or legs) are especially likely to occur in elderly patients. Older patients are usually more sensitive than younger adults to the effects of perphenazine and amitriptyline combination.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.

• Bepridil


• Cisapride


• Clorgyline


• Dronedarone


• Droperidol


• Furazolidone


• Grepafloxacin


• Iproniazid


• Isocarboxazid


• Levomethadyl


• Linezolid


• Mesoridazine


• Methylene Blue


• Metoclopramide


• Moclobemide


• Nialamide


• Pargyline


• Phenelzine


• Pimozide


• Procarbazine


• Ranolazine


• Selegiline


• Sparfloxacin


• Terfenadine


• Thioridazine


• Toloxatone


• Tranylcypromine

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Acecainide


• Alfuzosin


• Amiodarone


• Amisulpride


• Amoxapine


• Amprenavir


• Apomorphine


• Aprindine


• Arsenic Trioxide


• Asenapine


• Astemizole


• Atazanavir


• Azimilide


• Azithromycin


• Bretylium


• Chloral Hydrate


• Chloroquine


• Chlorpromazine


• Ciprofloxacin


• Citalopram


• Clarithromycin


• Clomipramine


• Clonidine


• Clozapine


• Crizotinib


• Dasatinib


• Desipramine


• Dextromethorphan


• Disopyramide


• Dofetilide


• Dolasetron


• Droperidol


• Enflurane


• Epinephrine


• Erythromycin


• Etilefrine


• Fentanyl


• Flecainide


• Fluconazole


• Fluoxetine


• Foscarnet


• Gatifloxacin


• Gemifloxacin


• Halofantrine


• Haloperidol


• Halothane


• Hydromorphone


• Ibutilide


• Iloperidone


• Imipramine


• Indacaterol


• Isoflurane


• Isradipine


• Lapatinib


• Levofloxacin


• Levorphanol


• Lidoflazine


• Lithium


• Lopinavir


• Lorcainide


• Lumefantrine


• Mefloquine


• Methadone


• Methoxamine


• Metrizamide


• Midodrine


• Milnacipran


• Moricizine


• Morphine


• Morphine Sulfate Liposome


• Moxifloxacin


• Nefazodone


• Nefopam


• Nilotinib


• Norepinephrine


• Norfloxacin


• Nortriptyline


• Octreotide


• Ofloxacin


• Ondansetron


• Oxilofrine


• Oxycodone


• Paliperidone


• Pazopanib


• Pentamidine


• Perflutren Lipid Microsphere


• Phenylephrine


• Posaconazole


• Procainamide


• Procarbazine


• Prochlorperazine


• Promethazine


• Propafenone


• Protriptyline


• Quetiapine


• Quinidine


• Quinine


• Rasagiline


• Risperidone


• Saquinavir


• Sematilide


• Sertindole


• Sertraline


• Sodium Phosphate


• Sodium Phosphate, Dibasic


• Sodium Phosphate, Monobasic


• Solifenacin


• Sorafenib


• Sotalol


• Spiramycin


• Sulfamethoxazole


• Sultopride


• Sunitinib


• Tapentadol


• Tedisamil


• Telavancin


• Telithromycin


• Tetrabenazine


• Toremifene


• Tramadol


• Trazodone


• Trifluoperazine


• Trimethoprim


• Trimipramine


• Vandetanib


• Vardenafil


• Vasopressin


• Vemurafenib


• Venlafaxine


• Voriconazole


• Ziprasidone


• Zolmitriptan


• Zotepine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Acenocoumarol


• Arbutamine


• Atomoxetine


• Belladonna


• Belladonna Alkaloids


• Betel Nut


• Bethanidine


• Carbamazepine


• Cimetidine


• Cinacalcet


• Clozapine


• Diazepam


• Dicumarol


• Evening Primrose


• Fluvoxamine


• Galantamine


• Guanethidine


• Meperidine


• Midodrine


• Orphenadrine


• Paroxetine


• Phenprocoumon


• Phenylalanine


• Phenytoin


• Procyclidine


• Rifapentine


• Ritonavir


• S-Adenosylmethionine


• St John's Wort


• Topiramate


• Trihexyphenidyl


• Warfarin

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use this medicine, or give you special instructions about the use of food, alcohol, or tobacco.

• Ethanol

Other Medical Problems

The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:

• Alcohol abuse—Certain side effects such as heat stroke may be more likely to occur

• Asthma (history of) or other lung disease or


• Bipolar disorder (manic-depressive illness) or


• Blood disease or


• Breast cancer or


• Difficult urination or


• Enlarged prostate or


• Epilepsy or other seizure disorders or


• Glaucoma or


• Heart or blood vessel disease or


• Mental illness (severe) or


• Parkinson's disease or


• Stomach or intestinal problems—Perphenazine and amitriptyline combination may make the condition worse

• Kidney disease or


• Liver disease—Higher blood levels of perphenazine and amitriptyline may occur, increasing the chance of side effects

• Overactive thyroid—Perphenazine and amitriptyline combination may cause an increased chance of serious effects on the heart

• Reye's syndrome—There may be an increased chance of unwanted effects on the liver

Proper Use of perphenazine and amitriptyline

This section provides information on the proper use of a number of products that contain perphenazine and amitriptyline. It may not be specific to Duo-Vil 2-10. Please read with care.

To lessen stomach upset, take this medicine immediately after meals or with food, unless your doctor has told you to take it on an empty stomach.

Do not take more of this medicine and do not take it more often than your doctor ordered. This is particularly important for elderly patients, since they are more sensitive to the effects of this medicine.

Sometimes perphenazine and amitriptyline combination must be taken for several weeks before its full effect is reached.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage form (tablets):
  
  • For certain mental and emotional conditions:
    
    • Adults—At first, 1 tablet taken three or four times a day. Your doctor may increase your dose if needed.
    
    
    • Children—Use and dose must be determined by your doctor.
    
    
  
  

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Precautions While Using Duo-Vil 2-10

Your doctor should check your progress at regular visits to allow dose adjustments and help reduce side effects.

Do not stop taking this medicine without first checking with your doctor. Your doctor may want you to reduce gradually the amount you are taking before stopping completely. This is to prevent side effects and to prevent your condition from becoming worse.

Do not take this medicine within two hours of taking antacids or medicine for diarrhea. Taking these products too close together may make this medicine less effective.

This medicine will add to the effects of alcohol and other CNS depressants (medicines that cause drowsiness). Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies, or colds; sedatives, tranquilizers, or sleeping medicine; prescription pain medicine or narcotics; barbiturates; medicine for seizures; or anesthetics, including some dental anesthetics. Check with your doctor before taking any of the above while you are using this medicine.

Before having any kind of surgery, dental treatment, or emergency treatment, tell the medical doctor or dentist in charge that you are taking this medicine. Taking perphenazine and amitriptyline combination together with medicines that are used during surgery or dental or emergency treatments may increase the CNS depressant effects.

The perphenazine and amitriptyline combination may cause some people to be agitated, irritable or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed. If you or your caregiver notice any of these adverse effects, tell your doctor right away.

This medicine may cause some people to become drowsy or less alert than they are normally, especially during the first few weeks of treatment. Even if this medicine is taken only at bedtime, it may cause some people to feel drowsy or less alert on arising. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are not alert.

Dizziness, lightheadedness, or fainting may occur, especially when you get up from a lying or sitting position. Getting up slowly may help. If the problem continues or gets worse, check with your doctor.

This medicine may make you sweat less, causing your body temperature to increase. Use extra care not to become overheated during exercise or hot weather while you are taking this medicine, since overheating may result in heat stroke. Also, hot baths or saunas may make you feel dizzy or faint.

Perphenazine and amitriptyline combination may cause dryness of the mouth. For temporary relief, use sugarless gum or candy, melt bits of ice in your mouth, or use a saliva substitute. However, if your mouth continues to feel dry for more than 2 weeks, check with your medical doctor or dentist. Continuing dryness of the mouth may increase the chance of dental disease, including tooth decay, gum disease, and fungus infections.

Perphenazine may cause your skin to be more sensitive to sunlight than it is normally. Exposure to sunlight, even for brief periods of time, may cause a skin rash, itching, redness or other discoloration of the skin, or a severe sunburn. When you begin taking this medicine:

• Stay out of direct sunlight, especially between the hours of 10:00 a.m. and 3:00 p.m., if possible.


• Wear protective clothing, including a hat. Also, wear sunglasses.


• Apply a sun block product that has a skin protection factor (SPF) of at least 15. Some patients may require a product with a higher SPF number, especially if they have a fair complexion. If you have any questions about this, check with your health care professional.


• Apply a sun block lipstick that has an SPF of at least 15 to protect your lips.


• Do not use a sunlamp or tanning bed or booth.

If you have a severe reaction from the sun, check with your doctor.

Duo-Vil 2-10 Side Effects

Along with its needed effects, perphenazine (included in this combination medicine) can sometimes cause serious side effects. Tardive dyskinesia (a movement disorder) may occur and may not go away after you stop using the medicine. Signs of tardive dyskinesia include fine, worm-like movements of the tongue, or other uncontrolled movements of the mouth, tongue, cheeks, jaw, or arms and legs. Other serious but rare side effects may also occur. These include severe muscle stiffness, fever, unusual tiredness or weakness, fast heartbeat, difficult breathing, increased sweating, loss of bladder control, and seizures (neuroleptic malignant syndrome). You and your doctor should discuss the good this medicine will do as well as the risks of taking it.

Stop taking this medicine and get emergency help immediately if any of the following effects occur:

Rare

• Convulsions (seizures)


• difficulty in breathing


• fast heartbeat


• fever


• high or low blood pressure


• increased sweating


• loss of bladder control


• muscle stiffness (severe)


• unusual tiredness or weakness


• unusually pale skin

Check with your doctor as soon as possible if any of the following side effects occur:

More common

• Blurred vision or any change in vision


• difficulty in speaking or swallowing


• fainting


• inability to move eyes


• lip smacking or puckering


• loss of balance control


• mask-like face


• muscle spasms, especially of face, neck, and back


• nervousness, restlessness, or need to keep moving


• puffing of cheeks


• rapid or fine, worm-like movements of tongue


• shuffling walk


• stiffness of arms and legs


• trembling and shaking of fingers and hands


• tic-like or twitching movements


• twisting movements of body


• uncontrolled chewing movements


• uncontrolled movements of arms or legs


• weakness of arms and legs

Less common

• Confusion


• constipation


• difficult urination


• eye pain


• hallucinations (seeing, hearing, or feeling things that are not there)


• increased skin sensitivity to sun


• shakiness


• slow pulse or irregular heartbeat

Rare

• Abdominal or stomach pain


• aching muscles or joints


• back or leg pain


• fever and chills


• hair loss


• hot, dry skin or lack of sweating


• irritability


• loss of appetite


• muscle weakness or twitching


• nausea, vomiting, or diarrhea


• nosebleeds


• prolonged, painful, inappropriate penile erection


• ringing, buzzing, or other unexplained noises in ears


• skin discoloration


• skin rash and itching


• sore throat and fever


• swelling of face and tongue


• swelling of testicles


• unusual bleeding or bruising


• yellow eyes or skin

Symptoms of overdose

• Agitation


• confusion


• convulsions (seizures)


• drowsiness (severe)


• enlarged pupils


• fast, slow, or irregular heartbeat


• fever


• hallucinations (seeing, hearing, or feeling things that are not there)


• shortness of breath or troubled breathing


• unusual tiredness or weakness (severe)


• vomiting (severe)

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Decreased sweating


• dizziness


• drowsiness


• dryness of mouth


• headache


• increased appetite for sweets


• nasal congestion


• tiredness or weakness (mild)


• unpleasant taste


• weight gain (unusual)

Less common

• Changes in menstrual period


• decreased sexual ability


• heartburn


• increased sweating


• swelling or pain in breasts or unusual secretion of milk

After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:

• Dizziness


• nausea or vomiting


• stomach pain


• trembling of fingers and hands


• symptoms of tardive dyskinesia, including lip smacking or puckering, puffing of cheeks, rapid or fine, worm-like movements of tongue, uncontrolled chewing movements, or uncontrolled movements of arms or legs

After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:

• Diarrhea


• headache


• irritability


• restlessness


• trouble in sleeping, with vivid dreams


• unusual excitement

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Duo-Vil 2-10 side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Duo-Vil 2-10 resources

• Duo-Vil 2-10 Side Effects (in more detail)
• Duo-Vil 2-10 Use in Pregnancy & Breastfeeding
• Duo-Vil 2-10 Drug Interactions
• Duo-Vil 2-10 Support Group
• 0 Reviews for Duo-Vil 2-10 - Add your own review/rating

• Etrafon 2-10 Concise Consumer Information (Cerner Multum)

Compare Duo-Vil 2-10 with other medications

• Agitation
• Anxiety
• Depression